JPH10502644A - 免疫機能の調整方法 - Google Patents
免疫機能の調整方法Info
- Publication number
- JPH10502644A JPH10502644A JP8504489A JP50448996A JPH10502644A JP H10502644 A JPH10502644 A JP H10502644A JP 8504489 A JP8504489 A JP 8504489A JP 50448996 A JP50448996 A JP 50448996A JP H10502644 A JPH10502644 A JP H10502644A
- Authority
- JP
- Japan
- Prior art keywords
- prolactin
- mammal
- profile
- time
- levels
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/225—Calcitonin gene related peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2257—Prolactin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Control Of Eletrric Generators (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.免疫システムの不全を病んでいる哺乳類の治療方法であって、該哺乳類は概 日プロラクチンリズムを有し、前記方法は、 治療が必要な該哺乳類のプロラクチンプロフィールを、該哺乳類と同種同性 の健康な個体の標準的なプロラクチンプロフィールと比較する工程と、 治療が必要な該哺乳類のプロラクチンプロフィールを、前記標準的なプロラ クチンプロフィールに適合させ、又は近似させるように調節する工程とを含み、 前記不全を改善又は修正する治療方法。 2.治療が必要な前記哺乳類の血中プロラクチンレベルを、24時間内の離隔し た間隔において測定し、該哺乳類のプロラクチンプロフィールを作成する工程を さらに含む、請求項1に記載の方法。 3.前記比較する工程が、前記哺乳類が、(i)離隔した2つの時点において、 標準的日中プロラクチンレベルよりも1SEM(標準平均誤差(Standard Error of the Mean))を越えて高い血中プロラクチンレベル、又は(ii)1つの時点に おいて、標準的日中プロラクチンレベルよりも2SEMを越えて高い血中プロラ クチンレベル、を有することを明らかとし、 前記調節する工程が、前記哺乳類に所定時刻(単数又は複数)においてプロ ラクチン低下剤を投与して、哺乳類の 日中プロラクチンプロフィールが、前記標準的日中プロラクチンプロフィールに 適合する又は近似するように、哺乳類の日中プロラクチンレベルを低下させる工 程を含む、請求項2に記栽の方法。 4.前記比較する工程が、前記哺乳類が、(i)離隔した2つの時点において、 標準的夜間プロラクチンレベルよりも1SEM(標準平均誤差(Standard Error of the Mean))を越えて低い血中プロラクチンレベル、又は(ii)1つの時点 において、標準的夜間プロラクチンレベルよりも2SEMを越えて低い血中プロ ラクチンレベル、を有することを明らかとし、 前記調節する工程が、前記哺乳類に所定時刻(単数又は複数)においてプロ ラクチン強化剤を投与して、哺乳類の夜間プロラクチンレベルが、前記標準的夜 間プロラクチンプロリールに適合する又は近似するように、哺乳類の夜間プロラ クチンレベルを増加させる工程を含む、請求項2に記載の方法。 5.前記プロラクチン低下剤がブロモクリプチンである、請求項3に記載の方法 。 6.前記プロラクチン強化剤が、メトクロプラミド、ドムペリドン、及び5−ヒ ドロキシトリプトファンからなる群より選択される、請求項4に記載の方法。 7.治療を必要とする前記哺乳類が、ヒトであり、前記ブロモクリプチンを一日 一人あたり0.8〜8.0mgの範囲の量で投与する、請求項5に記載の方法。 8.前記プロラクチン強化剤がメトクロプラミドであり、前記哺乳類がヒトであ り、該メトクロプラミドを一日一人あたり0.5〜5.0mgの範囲の量、投与 する、請求項6に記載の方法。 9.前記調節が、前記哺乳類のプロラクチンリズムが、前記標準的プロラクチン プロフィールに適合又は近似するようにリセットされるまで継続し、該調節の停 止後もリセットされた状態が持続する、請求項2に記載の方法。 10.免疫不全を病んでいる患者の治療方法であって、該方法は、 24時間の間の離隔する複数の時点のそれぞれにおける前記患者の血中プロ ラクチンレベルを、該患者と同性の健康なヒトの基線プロラクチンプロフィール の対応するプロラクチンレベルと比較する工程と、 患者のプロラクチンプロフィールが、基線プロラクチンプロフィールに近似 又は適合するように、該患者のプロラクチンレベルを調節する工程とを含み、そ れにより前記免疫不全を改善又は修正する、治療方法。 11.自己免疫疾患を病んでいる患者の治療方法であって、該方法は、 該患者の24時間内の離隔した複数の時点のそれぞれにおける血中プロラク チンレベルを、該患者と同性の健康なヒトの基線プロラクチンプロフィールの対 応するプロラクチンレベルと比較する工程と、 該患者のプロラクチンプロフィールが、基線プロラクチ ンプロフィールに近似又は適合するように、該患者のプロラクチンレベルを調節 する工程とを含み、それにより前記自己免疫疾患に関連する患者の少くとも一つ の症状を緩和する、治療方法。 12.免疫反応を上方調節する治療が必要な哺乳類の免疫反応を上方調節する方法 であって、該方法は、 該哺乳類に、24時間内の所定時刻に、増加したプロラクチンに対する哺乳 類の免疫システムのポジティブな免疫反応性の時間中に、哺乳類の血流中に追加 のプロラクチンを提供するように、プロラクチン強化剤を投与する工程を含む、 哺乳類の免疫反応を上方調節する方法。 13.前記投与が、プロラクチンに対するネガティブな免疫反応性の時間中に、前 記哺乳類の血流中に追加のプロラクチンを提供するものではない、請求項12に 記載の方法。 14.前記プロラクチン強化剤がプロラクチンであり、前記投与時刻が、増加した プロラクチンに対するポジティブな免疫反応性の時間中である、請求項12に記 載の方法。 15.前記強化剤がプロラクチン刺激剤であり、前記投与時刻が、増加したプロラ クチンに対するポジティブな免疫反応性の時間より前である、請求項12に記載 の方法。 16.前記プロラクチン強化剤が、メトクロプラミド、ハロペリドール、ピモジド 、フェノチアジン、ドムペリドン、スルピリド、クロルプロマジン、MAO阻害 剤であるセロトニン作動薬、パルジリン、メタドン、エストロゲン、トリプトフ ァン、5−ヒドロキシトリプトファン、メラトニン、 フルオキシタン、デキスフェンフルラミン、及びこれらの非毒性塩からなる群よ り選択される、請求項15に記載の方法。 17.前記哺乳類がマウスであり、ポジティブな免疫反応の時間が約4〜16HA LOである、請求項12に記載の方法。 18.前記哺乳類がヒトである、請求項12に記載の方法。 19.前記プロラクチン強化剤を、一日1kg当たり1−50μgの投薬範囲で投 与する、請求項17に記載の方法。 20.前記哺乳類がマウスであり、プロラクチンに対するポジティブな免疫反応性 の時間が、約4〜約12HALOであり、ネガティブな免疫反応が起こる時間が 、約20HALOの後且つ約3HALOの前である、請求項13の方法。 21.前記プロラクチン強化剤が、プロラクチン、メトクロプラミド、5−ヒドロ キシトリプトファン、及びドムペリドンからなる群より選択される、請求項20 に記載の方法。 22.前記患者の日中プロラクチンレベルが、離隔する2つの時点において基線プ ロラクチンプロフィールよりも1SEMを越えて高い場合、若しくは患者の日中 プロラクチンレベルが、1つの時点において基線プロラクチンプロフィールより も2SEMを越えて高い場合に、患者の前記プロラクチンレベルを、患者に所定 時間にプロラクチン低下剤を投与することによって調節する、請求項11に記載 の方法。 23.前記自己免疫疾患が、クローン病、リウマチ性関節炎、及び線維筋痛からな る群より選択される、請求項22に記載の方法。 24.前記プロラクチン低下剤がブロモクリプチンであり、前記所定時刻が約05 :00から約13:00の間である、請求項23に記載の方法。 25.前記ブロモクリプチンを、一日一人当たり0.8−8.0mgの範囲の量で 投与する、請求項24に記載の方法。 26.前記所定時刻が約05:00から10:30の間であり、前記ブロモクリプ チンの量が、一日一人あたり0.8−3.2mgの範囲内である、請求項25に 記載の方法。 27.前記患者の夜間プロラクチンレベルが、離隔する2つの時点において基線プ ロラクチンプロフィールよりも1SEMを越えて低い場合、若しくは患者の夜間 プロラクチンレベルが、1つの時点において基線プロラクチンプロフィールより も2SEMを越えて低い場合に、前記患者のプロラクチンレベルを、患者に所定 時刻にプロラクチン強化剤を投与することにより調節する、請求項11に記載の 方法。 28.免疫反応を強化する治療を必要とする哺乳類の免疫反応を強化する方法であ って、該方法は、該哺乳類に、哺乳類の血漿プロラクチンレベルを低下又は増加 させることにより、哺乳類の免疫反応を開始する能力が強化される所定時刻(単 数又は複数)に、プロラクチン低下剤及び/又は強化剤を投与する工程を含む、 哺乳類の免疫反応を強化する方法。 29.免疫不全を治療する必要のある哺乳類の免疫不全の治療方法であって、該方 法は、該哺乳類に、哺乳類の血漿プロラクチンレベルを低下又は増加させること により前記免疫 不全が改善される所定時刻(単数又は複数)に、プロラクチン低下剤及び/又は 強化剤を投与する工程を含む、哺乳類の免疫不全の治療方法。 30.請求項1〜29のいずれか一つの方法に使用するための組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US271,881 | 1994-07-07 | ||
US08/271,881 US5696128A (en) | 1994-07-07 | 1994-07-07 | Method of regulating immune function |
PCT/US1995/009419 WO1996001561A1 (en) | 1994-07-07 | 1995-07-07 | Method of regulating immune function |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008259671A Division JP2009046504A (ja) | 1994-07-07 | 2008-10-06 | 免疫機能調整のためのプロラクチン減少剤及び/又は増強剤の使用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10502644A true JPH10502644A (ja) | 1998-03-10 |
Family
ID=23037482
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8504489A Withdrawn JPH10502644A (ja) | 1994-07-07 | 1995-07-07 | 免疫機能の調整方法 |
JP2008259671A Pending JP2009046504A (ja) | 1994-07-07 | 2008-10-06 | 免疫機能調整のためのプロラクチン減少剤及び/又は増強剤の使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008259671A Pending JP2009046504A (ja) | 1994-07-07 | 2008-10-06 | 免疫機能調整のためのプロラクチン減少剤及び/又は増強剤の使用 |
Country Status (20)
Country | Link |
---|---|
US (5) | US5696128A (ja) |
EP (2) | EP0772396B1 (ja) |
JP (2) | JPH10502644A (ja) |
AT (2) | ATE249216T1 (ja) |
AU (1) | AU702392B2 (ja) |
BR (1) | BR9507858A (ja) |
CA (1) | CA2194501C (ja) |
CZ (1) | CZ4997A3 (ja) |
DE (2) | DE69531737T2 (ja) |
DK (2) | DK1275392T3 (ja) |
ES (2) | ES2333848T3 (ja) |
FI (1) | FI970059A (ja) |
HU (1) | HUT76727A (ja) |
IL (1) | IL114502A0 (ja) |
NO (1) | NO970038L (ja) |
NZ (1) | NZ290672A (ja) |
PT (2) | PT772396E (ja) |
SK (1) | SK1597A3 (ja) |
WO (1) | WO1996001561A1 (ja) |
ZA (1) | ZA955683B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003081829A (ja) * | 2001-09-13 | 2003-03-19 | Ajinomoto Co Inc | 概日リズム調整剤 |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5696128A (en) * | 1994-07-07 | 1997-12-09 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method of regulating immune function |
JP2001516341A (ja) * | 1997-01-21 | 2001-09-25 | ジェンザイム・コーポレーション | 造血細胞の増強 |
US6342611B1 (en) * | 1997-10-10 | 2002-01-29 | Cytovia, Inc. | Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof |
KR100261114B1 (ko) * | 1998-01-24 | 2000-07-01 | 박종헌 | 히스톤을 함유하는 류마티스 관절염 치료제 조성물 |
US6103748A (en) * | 1998-06-19 | 2000-08-15 | Bryan; Thomas B. | Method of treating an autoimmune disorder |
CA2404704A1 (en) * | 2000-04-21 | 2001-11-22 | David W. Robertson | Treatment of fibromyalgia and chronic fatigue syndrome |
GB0019357D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
US6277875B1 (en) | 2000-07-17 | 2001-08-21 | Andrew J. Holman | Use of dopamine D2/D3 receptor agonists to treat fibromyalgia |
WO2002012545A2 (en) | 2000-08-03 | 2002-02-14 | Cytovia, Inc. | Method of identifying immunosuppressive agents |
DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
US20070243240A9 (en) * | 2000-08-24 | 2007-10-18 | Fred Windt-Hanke | Transdermal therapeutic system |
DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
DE60229123D1 (de) * | 2001-02-20 | 2008-11-13 | Dinan Timothy Gerard | Behandlung von fibromyalgie mit pindolol |
US20020165246A1 (en) * | 2001-03-05 | 2002-11-07 | Andrew Holman | Administration of sleep restorative agents |
WO2002083141A1 (en) * | 2001-04-17 | 2002-10-24 | Pharmacia & Upjohn Company | Treatment of fibromyalgia and chronic fatigue syndrome |
US20030212085A1 (en) * | 2001-04-17 | 2003-11-13 | Mccall Robert B. | Treatment of fibromyalgia and chronic fatigue syndrome |
US8563525B2 (en) | 2004-01-12 | 2013-10-22 | Natrogen Therapeutics International, Inc. | Methods of treating an inflammatory-related disease |
US7582670B2 (en) * | 2001-12-13 | 2009-09-01 | Natrogen Therapeutics, Inc. | Methods of treating an inflammatory-related disease |
US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
AU2003215082B2 (en) * | 2002-02-07 | 2011-11-10 | Baylor College Of Medicine | Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy |
US20090311795A1 (en) * | 2002-03-21 | 2009-12-17 | Hinz Martin C | Bilateral control of functions traditionally regulated by only serotonin or only dopamine |
US20060110325A1 (en) * | 2003-02-21 | 2006-05-25 | Hinz Martin C | Serotonin and catecholamine segment optimization technology |
WO2003079886A2 (en) * | 2002-03-21 | 2003-10-02 | Hinz Martin C | Serotonin and catecholamine system segment optimization techonology |
US20070293571A1 (en) * | 2006-06-08 | 2007-12-20 | Hinz Martin C | Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes |
US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
US20040220153A1 (en) * | 2002-09-24 | 2004-11-04 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
EP1660530A2 (en) * | 2003-08-04 | 2006-05-31 | Advisys, Inc. | Canine specific growth hormone releasing hormone |
WO2006135733A2 (en) * | 2005-06-10 | 2006-12-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Modulation of peripheral clocks in adipose tissue |
US7507716B2 (en) * | 2005-07-06 | 2009-03-24 | Board Of Regents, The University Of Texas System | Method for treating pain with prolactin antagonists |
DE102005041613A1 (de) * | 2005-09-01 | 2007-03-08 | Ergonex Pharma Gmbh | Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom |
TWI392670B (zh) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途 |
US20100035886A1 (en) | 2007-06-21 | 2010-02-11 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
US8741918B2 (en) * | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
WO2008157845A1 (en) | 2007-06-21 | 2008-12-24 | Veroscience, Llc | Method of treating metabolic disorders and depression with dopamine receptor agonists |
CN101426268B (zh) * | 2007-11-02 | 2010-08-25 | 大唐移动通信设备有限公司 | 导频资源分配方法、系统和设备 |
US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
EP2470270A1 (en) * | 2009-07-31 | 2012-07-04 | AnaMar AB | Compounds for treatment of inflammation |
US9617517B2 (en) | 2011-05-02 | 2017-04-11 | National University Corporation Kumamoto University | Small chemical compound which promotes induction of differentiation of stem cells into insulin-producing cells and method for inducing differentiation of stem cells into insulin-producing cells using said small chemical compound |
US8431155B1 (en) | 2012-04-30 | 2013-04-30 | Veroscience Llc | Bromocriptine formulations |
PL3445362T3 (pl) | 2016-04-20 | 2022-05-30 | Veroscience Llc | Kompozycja i sposób leczenia zaburzeń metabolicznych |
US11382885B2 (en) | 2017-06-07 | 2022-07-12 | The Regents Of The University Of California | Compositions for treating fungal and bacterial biofilms and methods of using the same |
CA3079522A1 (en) | 2017-10-18 | 2019-04-25 | Veroscience Llc | Improved bromocriptine formulations |
WO2021061818A1 (en) | 2019-09-23 | 2021-04-01 | Veroscience Llc | Method for inducing tumor regression |
WO2024020641A1 (en) * | 2022-07-27 | 2024-02-01 | Macquarie University | Vascular endothelial growth factor inhibitors for the treatment of joint disorders |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL53452A (en) * | 1976-11-30 | 1980-12-31 | Pierpaoli W | Combination of drugs for the selective control of immune reactions |
EP0126630B1 (en) * | 1983-05-18 | 1987-09-16 | Monash University | The use of melatonin for the manufacture of a medicament |
CS253987B1 (en) * | 1986-05-07 | 1987-12-17 | Jiri Burkhard | Agent for encreasing the germinative activity of orchidaceous seeds |
DE3722383A1 (de) * | 1986-07-14 | 1988-01-28 | Sandoz Ag | Neue verwendung von bromocriptin |
US4837202A (en) * | 1987-09-14 | 1989-06-06 | Pitman-Moore, Inc. | Method for stimulating the immune system |
US5028591A (en) * | 1987-09-14 | 1991-07-02 | Pitman-Moore, Inc. | Method for stimulating the immune system |
US5344832A (en) * | 1990-01-10 | 1994-09-06 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates |
US5585347A (en) * | 1988-05-10 | 1996-12-17 | Ergo Science Incorporated | Methods for the determination and adjustment of prolactin daily rhythms |
GB8813339D0 (en) * | 1988-06-06 | 1988-07-13 | Sandoz Ltd | Improvements in/relating to organic compounds |
DK469989D0 (da) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
AU3419293A (en) * | 1991-12-23 | 1993-07-28 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College, The | A therapeutic process for the treatment of the pathologies of type II diabetes |
US5696128A (en) * | 1994-07-07 | 1997-12-09 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method of regulating immune function |
WO1994022451A1 (en) * | 1993-04-07 | 1994-10-13 | Oklahoma Medical Research Foundation | Selective regulation of b lymphocyte precursors by hormones |
US5519047A (en) * | 1994-04-20 | 1996-05-21 | University Of Utah Research Foundation | Immunomodulatory activity of exogenous melatonin following traumatic injury |
-
1994
- 1994-07-07 US US08/271,881 patent/US5696128A/en not_active Expired - Lifetime
-
1995
- 1995-06-02 US US08/459,114 patent/US5905083A/en not_active Expired - Lifetime
- 1995-06-02 US US08/458,960 patent/US5872133A/en not_active Expired - Lifetime
- 1995-07-07 ZA ZA955683A patent/ZA955683B/xx unknown
- 1995-07-07 DE DE69531737T patent/DE69531737T2/de not_active Expired - Lifetime
- 1995-07-07 IL IL11450295A patent/IL114502A0/xx unknown
- 1995-07-07 DK DK02017154T patent/DK1275392T3/da active
- 1995-07-07 DE DE69535996T patent/DE69535996D1/de not_active Expired - Lifetime
- 1995-07-07 DK DK95927448T patent/DK0772396T3/da active
- 1995-07-07 AU AU31479/95A patent/AU702392B2/en not_active Ceased
- 1995-07-07 SK SK15-97A patent/SK1597A3/sk unknown
- 1995-07-07 JP JP8504489A patent/JPH10502644A/ja not_active Withdrawn
- 1995-07-07 HU HU9700028A patent/HUT76727A/hu unknown
- 1995-07-07 CZ CZ9749A patent/CZ4997A3/cs unknown
- 1995-07-07 CA CA2194501A patent/CA2194501C/en not_active Expired - Fee Related
- 1995-07-07 ES ES02017154T patent/ES2333848T3/es not_active Expired - Lifetime
- 1995-07-07 NZ NZ290672A patent/NZ290672A/en unknown
- 1995-07-07 AT AT95927448T patent/ATE249216T1/de not_active IP Right Cessation
- 1995-07-07 EP EP95927448A patent/EP0772396B1/en not_active Expired - Lifetime
- 1995-07-07 EP EP02017154A patent/EP1275392B1/en not_active Expired - Lifetime
- 1995-07-07 AT AT02017154T patent/ATE440606T1/de not_active IP Right Cessation
- 1995-07-07 PT PT95927448T patent/PT772396E/pt unknown
- 1995-07-07 BR BR9507858A patent/BR9507858A/pt not_active Application Discontinuation
- 1995-07-07 WO PCT/US1995/009419 patent/WO1996001561A1/en active IP Right Grant
- 1995-07-07 PT PT02017154T patent/PT1275392E/pt unknown
- 1995-07-07 ES ES95927448T patent/ES2210305T3/es not_active Expired - Lifetime
-
1997
- 1997-01-06 NO NO970038A patent/NO970038L/no not_active Application Discontinuation
- 1997-01-07 FI FI970059A patent/FI970059A/fi unknown
- 1997-01-09 US US08/780,727 patent/US5872127A/en not_active Expired - Lifetime
-
1998
- 1998-12-03 US US09/204,839 patent/US6075020A/en not_active Expired - Lifetime
-
2008
- 2008-10-06 JP JP2008259671A patent/JP2009046504A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003081829A (ja) * | 2001-09-13 | 2003-03-19 | Ajinomoto Co Inc | 概日リズム調整剤 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10502644A (ja) | 免疫機能の調整方法 | |
JP3150343B2 (ja) | ブロモクリプチンを含有する加速放出組成物 | |
JP2007302701A (ja) | 哺乳類における新生物の成長を阻害するための薬剤 | |
EP0828492B1 (en) | Medicaments for preventing intervention-associated stenosis following non-bypass, invasive interventions | |
US9987268B2 (en) | Method of restoring the incretin effect | |
JP2002526411A (ja) | 網膜病理を治療するためのジルチアゼムの使用 | |
EP0833636B1 (en) | Method for inhibiting neoplastic disease in mammals | |
MXPA97009755A (en) | The use of an increment of prolactin to prepare useful compositions to inhibit neoplastic diseases in mamife | |
MXPA97000224A (en) | Method of regulation of the inm function | |
MXPA97009163A (en) | The use of a dopamine / proluctine reduction compound to prepare compositions to prevent associated stenosis with intervention after invasive interventions without deriva |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060425 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060721 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060904 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061025 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080610 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20081007 |